In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VBI Vaccines Inc.

www.vbivaccines.com

Latest From VBI Vaccines Inc.

Finance Watch: Investors Bet Billions On Big Biopharma Offerings

Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.

Financing Business Strategies

Finance Watch: ORIC Raises $120m In Another Pandemic Era Biopharma IPO

Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.

Financing Business Strategies

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Financing Innovation

VBI Is Ready To Take On HBV Vaccine Market

VBI’s Sci-B-Vac CONSTANT data firmly establishes the hepatitis B vaccine’s advantages over GSK’s longstanding Engerix-B, but it faces a tougher challenge with Heplisav-B from Dynavax. 

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • SciVac Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • VBI Vaccines Inc.
  • Senior Management
  • Jeff Baxter, Pres. & CEO
    Christopher McNulty, Head, Bus. Dev. & CFO
    David E Anderson, PhD, CSO
    Francisco Diaz-Mitoma, MD, PhD, CMO
    Nell Beattie, CBO
  • Contact Info
  • VBI Vaccines Inc.
    Phone: (617) 830-3031
    222 Third St., Ste. 2241
    P.O. Box 580 Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register